Vertical Sleeve Gastrectomy Lowers SGLT2/Slc5a2 Expression in the Mouse Kidney

被引:2
|
作者
Akalestou, Elina [1 ]
Lopez-Noriega, Livia [1 ]
Tough, Iain R. [2 ]
Hu, Ming [1 ]
Leclerc, Isabelle [1 ,3 ]
Cox, Helen M. [2 ]
Rutter, Guy A. [1 ,3 ,4 ]
机构
[1] Imperial Coll London, Div Diabet Endocrinol & Metab, Sect Cell Biol & Funct Genom, London, England
[2] Wolfson Ctr Age Related Dis, London, England
[3] Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ, Canada
[4] Nanyang Technol Univ, Lee Kong Chian Imperial Med Sch, Singapore, Singapore
基金
英国惠康基金; 欧盟地平线“2020”; 英国生物技术与生命科学研究理事会; 英国医学研究理事会;
关键词
Y GASTRIC BYPASS; IMPROVES GLUCOSE-HOMEOSTASIS; BARIATRIC SURGERY; TRANSPORTER SGLT2; PEPTIDE YY; SODIUM; DAPAGLIFLOZIN; MODULATION; ABSORPTION; INHIBITORS;
D O I
10.2337/db21-0768
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bariatric surgery improves glucose homeostasis, but the underlying mechanisms are not fully elucidated. Here, we show that the expression of sodium-glucose cotransporter 2 (SGLT2/Slc5a2) is reduced in the kidney of lean and obese mice following vertical sleeve gastrectomy (VSG). Indicating an important contribution of altered cotransporter expression to the impact of surgery, inactivation of the SGLT2/Slc5a2 gene by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 attenuated the effects of VSG, with glucose excursions following intraperitoneal injection lowered by similar to 30% in wild-type mice but by similar to 20% in SGLT2-null animals. The effects of the SGLT2 inhibitor dapaglifozin were similarly blunted by surgery. Unexpectedly, effects of dapaglifozin were still observed in SGLT2-null mice, consistent with the existence of metabolically beneficial off-target effects of SGLT2 inhibitors. Thus, we describe a new mechanism involved in mediating the glucose-lowering effects of bariatric surgery.
引用
收藏
页码:1623 / 1635
页数:13
相关论文
共 50 条
  • [21] Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
    Unno, Keiko
    Taguchi, Kyoko
    Takagi, Yoshiichi
    Hase, Tadashi
    Meguro, Shinichi
    Nakamura, Yoriyuki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [23] ISOLATED GLYCOSURIA IN A PATIENT WITH CONFIRMED SLC5A2 MUTATION
    Knoell, Sophia
    Abramovitz, Blaise
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S30 - S30
  • [24] SGLT2 inhibitors and kidney outcomes in the real world
    Smith, Steven M.
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [25] SGLT2 INHIBITION IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES
    Guthoff, M.
    Mahling, M.
    Nadalin, S.
    Heyne, N.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 32 - 32
  • [26] SGLT2 INHIBITORS IN KIDNEY TRANSPLANTATION: A MULTICENTER STUDY
    Garcia Carro, Clara
    Bedia Raba, Andrea
    Banegas Deras, Eduardo J.
    Alberto Vigara, Luis
    Valero San Cecilio, Rosalia
    Cruzado Vega, Leonidas
    Gavela, Eva
    Gonzalez Garcia, M. Elena
    Perez-Flores, Isabel
    Sanchez-Bielsa, Francisco
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I884 - I884
  • [27] SGLT2 inhibitors to prevent diabetic kidney disease
    Fioretto, Paola
    Vettor, Roberto
    Pontremoli, Roberto
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (01): : 4 - 5
  • [28] SGLT2 Inhibitors: Will They Change the Face of Kidney Care?
    Hurtado, Tucker B.
    Staudt, Meghan
    Robinson, Jennifer
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 732 - 733
  • [29] SGLT2 inhibitors for treatment of chronic kidney disease
    Davis, S.
    SA PHARMACEUTICAL JOURNAL, 2024, 91 (02) : 26 - 28
  • [30] Kidney-Protective Effects of SGLT2 Inhibitors
    Palmer, Biff F.
    Clegg, Deborah J.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (02): : 279 - 289